Table 1.
Patients characteristics
| Characteristics | N = 111 |
|---|---|
| Age | |
| Years | 65 (40-80) |
| Sex, n (%) | |
| F | 45 (40.5) |
| M | 66 (59.5) |
| Performance status, n (%) | |
| 0 | 64 (57.7) |
| 1 | 43 (38.7) |
| 2 | 4 (3.6) |
| Tumor location, n (%) | |
| Rectum | 32 (28.8) |
| Right colon | 34 (30.6) |
| Left colon | 45 (40.5) |
| Primary tumor resection, n (%) | |
| Yes | 67 (60.4) |
| No | 44 (39.6) |
| Grading, n (%) | |
| 1 | 4 (3.6) |
| 2 | 41 (37) |
| 3 | 20 (18) |
| NA | 46 (41.4) |
| Mucinous histology, n (%) | |
| Yes | 18 (16.2) |
| No | 79 (71.2) |
| NA | 14 (12.6) |
| Microsatellite instability, n (%) | |
| MSI | 0 (0) |
| MSS | 61 (55) |
| NA | 50 (45) |
| Metastatic disease at initial diagnosis, n (%) | |
| Yes | 73 (65.8) |
| No | 38 (34.2) |
| Number of metastatic sites, n (%) | |
| <3 | 79 (71.2) |
| ≥3 | 32 (28.8) |
| Liver metastasis, n (%) | |
| Yes | 71 (64) |
| No | 40 (36) |
| Lung metastasis, n (%) | |
| Yes | 46 (41.4) |
| No | 65 (58.6) |
| Peritoneal metastasis, n (%) | |
| Yes | 21 (18.9) |
| No | 90 (81.1) |
| Nodes metastasis, n (%) | |
| Yes | 19 (17.1) |
| No | 92 (82.9) |
| CEA levels, n (%) | |
| <5 | 18 (16.2) |
| ≥5 | 68 (61.3) |
| NA | 25 (22.5) |
| Type of first-line treatment, n (%) | |
| Oxaliplatin-based doublet | 66 (59.5) |
| Irinotecan-based doublet | 29 (26.1) |
| FOLFOXIRI triplet | 16 (14.4) |
| Antiangiogenic use in combination with first-line chemotherapy, n (%) | |
| Yes | 80 (66.1) |
| No | 31 (33.9) |
CEA, carcinoembryonic antigen; F, female; M, male; MSI, microsatellite instability: MSS, microsatellite stable. NA, not available.